Table 2.

Serious adverse events

SAE, n (%)	Lyophilized palivizumab (n = 202)	Liquid palivizumab (n = 211)	Total (n = 413)
Total number of subjects reporting ≥1 SAE	12 (5.9)	18 (8.5)	30 (7.3)
Bronchiolitis	3 (1.5)	6 (2.8)	9 (2.2)
Gastroenteritis	2 (1.0)	2 (0.9)	4 (1.0)
Respiratory distress	2 (1.0)	0 (0.0)	2 (0.5)
Viral infection	0 (0.0)	2 (0.9)	2 (0.5)
Cleft lip	1 (0.5)	1 (0.5)	2 (0.5)
Inguinal hernia	1 (0.5)	1 (0.5)	2 (0.5)
Abscess	1 (0.5)	0 (0.0)	1 (0.2)
Anal fissure	0 (0.0)	1 (0.5)	1 (0.2)
Apnea	1 (0.5)	0 (0.0)	1 (0.2)
Asphyxia	1 (0.5)	0 (0.0)	1 (0.2)
Bronchopneumonia	0 (0.0)	1 (0.5)	1 (0.2)
Cellulitis	0 (0.0)	1 (0.5)	1 (0.2)
Complex partial seizures	0 (0.0)	1 (0.5)	1 (0.2)
Convulsions	0 (0.0)	1 (0.5)	1 (0.2)
Craniosynostosis	0 (0.0)	1 (0.5)	1 (0.2)
Dehydration	0 (0.0)	1 (0.5)	1 (0.2)
Dyspnea	1 (0.5)	0 (0.0)	1 (0.2)
Failure to thrive	1 (0.5)	0 (0.0)	1 (0.2)
Gastroenteritis rotavirus	0 (0.0)	1 (0.5)	1 (0.2)
Gastroesophageal reflux disease	0 (0.0)	1 (0.5)	1 (0.2)
Hydronephrosis	0 (0.0)	1 (0.5)	1 (0.2)
Infectious croup	0 (0.0)	1 (0.5)	1 (0.2)
Lymphadenitis	0 (0.0)	1 (0.5)	1 (0.2)
Occult blood positive	1 (0.5)	0 (0.0)	1 (0.2)
Umbilical hernia	0 (0.0)	1 (0.5)	1 (0.2)

SAE Serious adverse event